Disease on EC 1.14.11.27 - [histone-H3]-lysine-36 demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Adenocarcinoma
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Adenocarcinoma of Lung
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Arthritis, Rheumatoid
Cystathionine-?-lyase ameliorates the histone demethylase JMJD3-mediated autoimmune response in rheumatoid arthritis.
Histone demethylase JMJD3 regulates fibroblast-like synoviocyte-mediated proliferation and joint destruction in rheumatoid arthritis.
Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells.
Ataxia Telangiectasia
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Atherosclerosis
Identification of the histone lysine demethylase KDM4A/JMJD2A as a novel epigenetic target in M1 macrophage polarization induced by oxidized LDL.
Azoospermia
Expression ratio of histone demethylase KDM3A to protamine-1 mRNA is predictive of successful testicular sperm extraction in men with obstructive and non-obstructive azoospermia.
Blast Crisis
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Bone Diseases, Metabolic
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Brain Diseases
KDM4B histone demethylase and G9a regulate expression of vascular adhesion proteins in cerebral microvessels.
Brain Neoplasms
KDM2B Recruitment of the Polycomb Group Complex, PRC1.1, Requires Cooperation between PCGF1 and BCORL1.
Breast Neoplasms
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Cancer-associated alteration of pericentromeric heterochromatin may contribute to chromosome instability.
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
ERR? protein is stabilized by LSD1 in a demethylation-independent manner.
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Genomic amplification and a role in drug-resistance for the KDM5A histone demethylase in breast cancer.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
JMJD2A-dependent silencing of Sp1 in advanced breast cancer promotes metastasis by downregulation of DIRAS3.
Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM4 inhibition targets breast cancer stem-like cells.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53.
Mammalian lysine histone demethylase KDM2A regulates E2F1-mediated gene transcription in breast cancer cells.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
Oncogenic features of the JMJD2A histone demethylase in breast cancer.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
PELP1 overexpression in the mouse mammary gland results in the development of hyperplasia and carcinoma.
PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation.
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients.
The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer.
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
UTX and MLL4 Coordinately Regulate Transcriptional Programs for Cell Proliferation and Invasiveness in Breast Cancer Cells.
UTX promotes hormonally responsive breast carcinogenesis through feed-forward transcription regulation with estrogen receptor.
Carcinogenesis
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Crystal Structure and Functional Analysis of JMJD5 Indicate an Alternate Specificity and Function.
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Functional characterization of JMJD2A, a histone deacetylase- and retinoblastoma-binding protein.
High-Throughput TR-FRET Assays for Identifying Inhibitors of LSD1 and JMJD2C Histone Lysine Demethylases.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone lysine demethylases in Drosophila melanogaster.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and functional implication of nuclear localization signals in the N-terminal domain of JMJD5.
In vivo CRISPR screening unveils histone demethylase UTX as an important epigenetic regulator in lung tumorigenesis.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.
JMJD5 is a potential oncogene for colon carcinogenesis.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
KDM2B/FBXL10 targets c-Fos for ubiquitylation and degradation in response to mitogenic stimulation.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Nuclear GSK3? promotes tumorigenesis by phosphorylating KDM1A and inducing its deubiquitylation by USP22.
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Post-Transcriptional Regulation of the GASC1 Oncogene with Active Tumor-Targeted siRNA-Nanoparticles.
Rare germline alterations in cancer-related genes associated with the risk of multiple primary tumor development.
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
The Emerging Role of Lysine Demethylases in DNA Damage Response: Dissecting the recruitment mode of KDM4D/JMJD2D to DNA damage sites.
The H3K36 demethylase Jhdm1b/Kdm2b regulates cell proliferation and senescence through p15(Ink4b).
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Carcinoma
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and characterization of JMJD2 family genes in silico.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C.
Normal stroma suppresses cancer cell proliferation via mechanosensitive regulation of JMJD1a-mediated transcription.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Carcinoma in Situ
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Carcinoma, Embryonal
The histone demethylase Kdm3a is essential to progression through differentiation.
Carcinoma, Hepatocellular
Depletion of histone demethylase KDM5B inhibits cell proliferation of hepatocellular carcinoma by regulation of cell cycle checkpoint proteins p15 and p27.
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
Hepatitis B virus X protein induces the histone H3 lysine 9 trimethylation on the promoter of p16 gene in hepatocarcinogenesis.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Lysine demethylase LSD1 coordinates glycolytic and mitochondrial metabolism in hepatocellular carcinoma cells.
The histone demethylase JMJD1A regulates adrenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia.
Carcinoma, Non-Small-Cell Lung
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
Carcinoma, Renal Cell
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
KDM3A is not associated with metastasis and prognosis of breast cancer.
The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma.
Carcinoma, Squamous Cell
A novel amplicon at 9p23 - 24 in squamous cell carcinoma of the esophagus that lies proximal to GASC1 and harbors NFIB.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
Notch-effector CSL promotes squamous cell carcinoma by repressing histone demethylase KDM6B.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Cardiomegaly
The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes.
The histone demethylase PHF8 represses cardiac hypertrophy upon pressure overload.
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
Cardiomyopathy, Hypertrophic
The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice.
CHARGE Syndrome
Knockdown of fbxl10/kdm2bb rescues chd7 morphant phenotype in a zebrafish model of CHARGE syndrome.
Chondrosarcoma
Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.
Chordoma
365?Epigenetic Profiling Reveals a Unique Histone Code in Chordoma.
Colitis
Inhibition of KDM4A activity as a strategy to suppress interleukin-6 production and attenuate colitis induction.
Colonic Neoplasms
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
Epigenetic regulation of E-cadherin expression by the histone demethylase UTX in colon cancer cells.
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Histone Demethylases in Colon Cancer.
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
KDM6B/JMJD3 histone demethylase is induced by vitamin D and modulates its effects in colon cancer cells.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
Colorectal Neoplasms
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Clinical Significance of Histone Demethylase NO66 in Invasive Colorectal Cancer.
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
Histone Demethylase Gene PHF2 Is Mutated in Gastric and Colorectal Cancers.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase KDM3A is required for enhancer activation of hippo target genes in colorectal cancer.
Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells.
Histone demethylase PHF8 accelerates the progression of colorectal cancer and can be regulated by miR-488 in vitro.
JIB-04, A Small Molecule Histone Demethylase Inhibitor, Selectively Targets Colorectal Cancer Stem Cells by Inhibiting the Wnt/?-Catenin Signaling Pathway.
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
Silencing of JMJD2B induces cell apoptosis via mitochondria-mediated and death receptor-mediated pathway activation in colorectal cancer.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Diabetes Mellitus, Type 1
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Diabetes Mellitus, Type 2
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Diabetic Nephropathies
Histone demethylase UTX is a therapeutic target for diabetic kidney disease.
Endometrial Neoplasms
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
KDM4B and KDM4A promote endometrial cancer progression by regulating androgen receptor, c-myc, and p27kip1.
Epilepsy
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Esophageal Neoplasms
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Esophageal Squamous Cell Carcinoma
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Identification and characterization of JMJD2 family genes in silico.
Oncogenic features of PHF8 histone demethylase in esophageal squamous cell carcinoma.
The Prognostic Significance of Histone Demethylase UTX in Esophageal Squamous Cell Carcinoma.
Familial Primary Pulmonary Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Fanconi Anemia
Fanconi Anemia FANCM/FNCM-1 and FANCD2/FCD-2 Are Required for Maintaining Histone Methylation Levels and Interact with the Histone Demethylase LSD1/SPR-5 in
Fibroadenoma
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Gastritis
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
Gastrointestinal Stromal Tumors
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Genetic Diseases, Inborn
LSD1/KDM1A mutations associated to a newly described form of intellectual disability impair demethylase activity and binding to transcription factors.
Glioblastoma
Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance.
Regulation of the JMJD3 (KDM6B) histone demethylase in glioblastoma stem cells by STAT3.
Small molecules targeting histone demethylase genes (KDMs) inhibit growth of temozolomide-resistant glioblastoma cells.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma.
Glioma
Downregulation of KDM4A Suppresses the Survival of Glioma Cells by Promoting Autophagy.
Hairless regulates p53 target genes to exert tumor suppressive functions in glioblastoma.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
KDM1 is a novel therapeutic target for the treatment of gliomas.
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2B.
The pharmacological role of histone demethylase JMJD3 inhibitor GSK-J4 on glioma cells.
Hematologic Diseases
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Hematologic Neoplasms
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Hepatitis B
Hepatocyte Factor JMJD5 Regulates Hepatitis B Virus Replication through Interaction with HBx.
Herpes Simplex
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Herpesviridae Infections
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Hodgkin Disease
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
Huntington Disease
Systematic genetic interaction studies identify histone demethylase Utx as potential target for ameliorating Huntington's disease.
Hyperglycemia
Epigenetic modifications of Nrf2-mediated glutamate-cysteine ligase: implications for the development of diabetic retinopathy and the metabolic memory phenomenon associated with its continued progression.
Hypersensitivity
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Hypertension
Long Noncoding RNA MANTIS Facilitates Endothelial Angiogenic Function.
Hypertension, Pulmonary
Histone demethylase JARID1B regulates proliferation and migration of pulmonary arterial smooth muscle cells in mice with chronic hypoxia-induced pulmonary hypertension via nuclear factor-kappa B (NFkB).
Infection
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
JMJD5 is a potential oncogene for colon carcinogenesis.
Role of Serum Amyloid A, Granulocyte-Macrophage Colony-Stimulating Factor, and Bone Marrow Granulocyte-Monocyte Precursor Expansion in Segmented Filamentous Bacterium-Mediated Protection from Entamoeba histolytica.
Targeting the JMJD2 histone demethylases to epigenetically control herpesvirus infection and reactivation from latency.
Infertility, Male
Histone Demethylase JHDM2A Is Involved in Male Infertility and Obesity.
Intellectual Disability
A Drosophila Model of Intellectual Disability Caused by Mutations in the Histone Demethylase KDM5.
An atypical 12q24.31 microdeletion implicates six genes including a histone demethylase KDM2B and a histone methyltransferase SETD1B in syndromic intellectual disability.
Crystal structure of the PHF8 Jumonji domain, an Nepsilon-methyl lysine demethylase.
Epigenetic regulation in human brain-focus on histone lysine methylation.
Mechanisms of Origin, Phenotypic Effects and Diagnostic Implications of Complex Chromosome Rearrangements.
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.
PHF8, a gene associated with cleft lip/palate and mental retardation, encodes for an N{varepsilon}-dimethyl lysine demethylase.
Kidney Neoplasms
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
Latent Autoimmune Diabetes in Adults
Reduced Histone H3 Lysine 9 Methylation Contributes to the Pathogenesis of Latent Autoimmune Diabetes in Adults via Regulation of SUV39H2 and KDM4C.
Leukemia
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Fbxl10 overexpression in murine hematopoietic stem cells induces leukemia involving metabolic activation and upregulation of Nsg2.
Histone demethylase JMJD2B coordinates H3K4/H3K9 methylation and promotes hormonally responsive breast carcinogenesis.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Novel potent inhibitors of the histone demethylase KDM1A (LSD1), orally active in a murine promyelocitic leukemia model.
Report of the First Clinical Case of a Moroccan Kabuki Patient with a Novel MLL2 Mutation.
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
USP7 Cooperates with NOTCH1 to Drive the Oncogenic Transcriptional Program in T-Cell Leukemia.
Utx loss causes myeloid transformation.
[Expression of histone demethylase lysine specific demethylase 1 in acute leukemia and its clinical significance].
Leukemia, Erythroblastic, Acute
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Leukemia, Lymphocytic, Chronic, B-Cell
Unraveling KDM4 histone demethylase expression and its association with adverse cytogenetic findings in chronic lymphocytic leukemia.
Leukemia, Lymphoid
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Histone demethylase RBP2 decreases miR-21 in blast crisis of chronic myeloid leukemia.
Leukemia, Myeloid, Acute
JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia.
KDM2b/JHDM1b, an H3K36me2-specific demethylase, is required for initiation and maintenance of acute myeloid leukemia.
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
Utx loss causes myeloid transformation.
Leukemia, Promyelocytic, Acute
The Histone Demethylase PHF8 Governs Retinoic Acid Response in Acute Promyelocytic Leukemia.
Leukemia, T-Cell
LSD1-mediated epigenetic modification is required for TAL1 function and hematopoiesis.
Liver Neoplasms
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Lung Neoplasms
A Coding Single-Nucleotide Polymorphism in Lysine Demethylase KDM4A Associates with Increased Sensitivity to mTOR Inhibitors.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Epigenetic modifications in KDM lysine demethylases associate with survival of early-stage NSCLC.
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Histone demethylase JARID1B/KDM5B promotes aggressiveness of non-small cell lung cancer and serves as a good prognostic predictor.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Influence of the KDM4A rs586339 polymorphism on overall survival in Asian non-small-cell lung cancer patients.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Taxane-Platin-Resistant Lung Cancers Co-develop Hypersensitivity to JumonjiC Demethylase Inhibitors.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase PHF8 is an oncogenic protein in human non-small cell lung cancer.
The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.
Transcriptional Repression of Histone Deacetylase 3 by the Histone Demethylase KDM2A Is Coupled to Tumorigenicity of Lung Cancer Cells.
Lupus Erythematosus, Systemic
Histone demethylase JMJD3 regulates CD11a expression through changes in histone H3K27 tri-methylation levels in CD4+ T cells of patients with systemic lupus erythematosus.
JHDM1D and HDAC1-3 mRNA expression levels in peripheral blood mononuclear cells of patients with systemic lupus erythematosus.
Lymphoma
Cooperative epigenetic modulation by cancer amplicon genes.
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Lymphoma, B-Cell
FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
Lymphoma, B-Cell, Marginal Zone
Mucosa-Associated Lymphoid Tissue Lymphoma: Novel Translocations Including Rearrangements of ODZ2, JMJD2C, and CNN3.
Macular Degeneration
Histone Demethylase Expression Enhances Human Somatic Cell Nuclear Transfer Efficiency and Promotes Derivation of Pluripotent Stem Cells.
Medulloblastoma
The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.
Memory Disorders
Deletion of JMJD2B in neurons leads to defective spine maturation, hyperactive behavior and memory deficits in mouse.
Environmental enrichment reverses histone methylation changes in the aged hippocampus and restores age-related memory deficits.
Increase in GFAP-positive astrocytes in histone demethylase GASC1/KDM4C/JMJD2C hypomorphic mutant mice.
Mental Retardation, X-Linked
A distinctive gene expression fingerprint in mentally retarded male patients reflects disease-causing defects in the histone demethylase KDM5C.
A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation.
A PHF8 homolog in C. elegans promotes DNA repair via homologous recombination.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Stabilization of histone demethylase PHF8 by USP7 promotes breast carcinogenesis.
The histone demethylase PHF8 is essential for cytoskeleton dynamics.
The X-linked mental retardation gene PHF8 is a histone demethylase involved in neuronal differentiation.
Mesothelioma
KDM6B histone demethylase is an epigenetic regulator of estrogen receptor ? expression in human pleural mesothelioma.
Metabolic Syndrome
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Multiple Myeloma
Triptolide induces cell-cycle arrest and apoptosis of human multiple myeloma cells in vitro via altering expression of histone demethylase LSD1 and JMJD2B.
Myelodysplastic Syndromes
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Nasopharyngeal Carcinoma
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
Neoplasm Metastasis
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
Binding of the JmjC demethylase JARID1B to LSD1/NuRD suppresses angiogenesis and metastasis in breast cancer cells by repressing chemokine CCL14.
Dependence receptor UNC5A restricts luminal to basal breast cancer plasticity and metastasis.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A as a prognostic marker of oral squamous cell carcinoma: Evidence from tissue microarray studies in a multicenter cohort.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
Neoplasms
4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
A Lysine (K)-specific demethylase 2B (KDM2B)-let-7-Enhancer of Zester Homolog 2 (EZH2) pathway regulates cell cycle progression and senescence in primary cells.
A polymorphism in JMJD2C alters the cleavage by caspase-3 and the prognosis of human breast cancer.
A potential common role of the Jumonji C domain-containing 1A histone demethylase and chromatin remodeler ATRX in promoting colon cancer.
A Rhodium(III)-Based Inhibitor of Lysine-Specific Histone Demethylase 1 as an Epigenetic Modulator in Prostate Cancer Cells.
A small molecule modulates Jumonji histone demethylase activity and selectively inhibits cancer growth.
A systematic study of the cellular metabolic regulation of Jhdm1b in tumor cells.
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1.
Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
Advances in the development of histone lysine demethylase inhibitors.
Altering the Course of Small Cell Lung Cancer: Targeting Cancer Stem Cells via LSD1 Inhibition.
An epigenetic role for PRL-3 as a regulator of H3K9 methylation in colorectal cancer.
An RNA Aptamer Targeting the Receptor Tyrosine Kinase PDGFR? Induces Anti-tumor Effects through STAT3 and p53 in Glioblastoma.
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Ascorbate antagonizes nickel ion to regulate JMJD1A expression in kidney cancer cells.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
Biology and targeting of the Jumonji-domain histone demethylase family in childhood neoplasia: a preclinical overview.
Combination treatment of acute myeloid leukemia cells with DNMT and HDAC inhibitors: predominant synergistic gene downregulation associated with gene body demethylation.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Cooperative demethylation by JMJD2C and LSD1 promotes androgen receptor-dependent gene expression.
Correction to: Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
CTCF-KDM4A complex correlates with histone modifications that negatively regulate CHD5 gene expression in cancer cell lines.
Depletion of Histone Demethylase Jarid1A Resulting in Histone Hyperacetylation and Radiation Sensitivity Does Not Affect DNA Double-Strand Break Repair.
Depletion of JMJD5 sensitizes tumor cells to microtubule-destabilizing agents by altering microtubule stability.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Differential proteome profiling of pleural effusions from lung cancer and benign inflammatory disease patients.
Discovery of tranylcypromine analogs with an acylhydrazone substituent as LSD1 inactivators: Design, synthesis and their biological evaluation.
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
Down-regulation of JMJD5 suppresses metastasis and induces apoptosis in oral squamous cell carcinoma by regulating p53/NF-?B pathway.
Effects of RNA interference-mediated gene silencing of JMJD2A on human breast cancer cell line MDA-MB-231 in vitro.
Elevated expression of histone demethylase PHF8 associates with adverse prognosis in patients of laryngeal and hypopharyngeal squamous cell carcinoma.
Enhancement of Proliferation and Invasion of Gastric Cancer Cell by KDM5C Via Decrease in p53 Expression.
Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
Epigenetic activation of AP1 promotes squamous cell carcinoma metastasis.
Epigenetic control and cancer: the potential of histone demethylases as therapeutic targets.
Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer.
Epigenetic silencing of JMJD5 promotes the proliferation of hepatocellular carcinoma cells by down-regulating the transcription ofCDKN1A686.
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Epstein-Barr Virus Nuclear Antigen 3C Inhibits Expression of COBLL1 and the ADAM28-ADAMDEC1 Locus via Interaction with the Histone Lysine Demethylase KDM2B.
ERR? protein is stabilized by LSD1 in a demethylation-independent manner.
Erratum to: JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
Expression and effects of JMJD2A histone demethylase in endometrial carcinoma.
Expression of JMJD2A in infiltrating duct carcinoma was markedly higher than fibroadenoma, and associated with expression of ARHI, p53 and ER in infiltrating duct carcinoma.
Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer.
From histones to ribosomes: a chromatin regulator tangoes with translation.
GASC1 expression in lung carcinoma is associated with smoking and prognosis of squamous cell carcinoma.
Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer.
Genetic associations of 115 polymorphisms with cancers of the upper aerodigestive tract across 10 European countries: the ARCAGE project.
Genome-wide association study in esophageal cancer using GeneChip mapping 10K array.
Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer.
Gentle, fast and effective crystal soaking by acoustic dispensing.
Getting to the heart of the matter in cancer: Novel approaches to targeting cancer stem cells.
Heat shock protein 90 (Hsp90) selectively regulates the stability of KDM4B/JMJD2B histone demethylase.
HIF-1?-induced histone demethylase JMJD2B contributes to the malignant phenotype of colorectal cancer cells via an epigenetic mechanism.
Histone demethylase GASC1, a potential prognostic and predictive marker in esophageal squamous cell carcinoma.
Histone demethylase GASC1--a potential prognostic and predictive marker in invasive breast cancer.
Histone demethylase JARID1B promotes cell proliferation but is downregulated by N-Myc oncoprotein.
Histone demethylase JARID1C inactivation triggers genomic instability in sporadic renal cancer.
Histone demethylase JARID1C promotes breast cancer metastasis cells via down regulating BRMS1 expression.
Histone demethylase JMJD1A promotes colorectal cancer growth and metastasis by enhancing Wnt/?-catenin signaling.
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone Demethylase JMJD2B Functions as a Co-Factor of Estrogen Receptor in Breast Cancer Proliferation and Mammary Gland Development.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Histone Demethylase JMJD2D Interacts With ?-Catenin to Induce Transcription and Activate Colorectal Cancer Cell Proliferation and Tumor Growth in Mice.
Histone demethylase JMJD3 at the intersection of cellular senescence and cancer.
Histone demethylase JMJD5 is essential for embryonic development.
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase KDM2B regulates lineage commitment in normal and malignant hematopoiesis.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Histone Demethylase KDM4B Promotes DNA Damage by Activating Long Interspersed Nuclear Element-1.
Histone demethylase KDM4D promotes gastrointestinal stromal tumor progression through HIF1?/VEGFA signalling.
Histone demethylase KDM5A inhibits glioma cells migration and invasion by down regulating ZEB1.
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
Histone demethylase LSD2 acts as an E3 ubiquitin ligase and inhibits cancer cell growth through promoting proteasomal degradation of OGT.
Histone demethylase lysine demethylase 5B in development and cancer.
Histone demethylase PHF8 promotes epithelial to mesenchymal transition and breast tumorigenesis.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Histone H3 binding to the PHD1 domain of histone demethylase KDM5A enables active site remodeling.
Histone lysine demethylases in Drosophila melanogaster.
HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372.
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
Hypoxia and Hormone-Mediated Pathways Converge at the Histone Demethylase KDM4B in Cancer.
Identification and functional analysis of 9p24 amplified genes in human breast cancer.
Identification of a novel gene, GASC1, within an amplicon at 9p23-24 frequently detected in esophageal cancer cell lines.
Identification of Deregulated Signaling Pathways in Jurkat Cells in Response to a Novel Acylspermidine Analogue-N4-Erucoyl Spermidine.
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
Impairment of Preimplantation Porcine Embryo Development by Histone Demethylase KDM5B Knockdown Through Disturbance of Bivalent H3K4me3-H3K27me3 Modifications.
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Inhibiting interactions of lysine demethylase LSD1 with snail/slug blocks cancer cell invasion.
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
Inhibition of histone demethylase, LSD2 (KDM1B), attenuates DNA methylation and increases sensitivity to DNMT inhibitor-induced apoptosis in breast cancer cells.
Integrated genomic analyses identify KDM1A's role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer.
JARID1 Histone Demethylases: Emerging Targets in Cancer.
JARID1B modulates lung cancer cell proliferation and invasion by regulating p53 expression.
JMJD1A promotes tumorigenesis and forms a feedback loop with EZH2/let-7c in NSCLC cells.
JMJD2A attenuation affects cell cycle and tumourigenic inflammatory gene regulation in lipopolysaccharide stimulated neuroectodermal stem cells.
JMJD2A contributes to breast cancer progression through transcriptional repression of the tumor suppressor ARHI.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
JMJD2A promotes cellular transformation by blocking cellular senescence through transcriptional repression of the tumor suppressor CHD5.
JMJD2A promotes the Warburg effect and nasopharyngeal carcinoma progression by transactivating LDHA expression.
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Jmjd2c histone demethylase enhances the expression of Mdm2 oncogene.
JMJD5 interacts with p53 and negatively regulates p53 function in control of cell cycle and proliferation.
JMJD5 is a potential oncogene for colon carcinogenesis.
JMJD5 regulates PKM2 nuclear translocation and reprograms HIF-1?-mediated glucose metabolism.
Jumonji domain containing 2A predicts prognosis and regulates cell growth in lung cancer depending on miR-150.
Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer.
JumonjiC demethylase inhibitors show potential for targeting chemotherapy-resistant lung cancers.
KDM1A promotes tumor cell invasion by silencing TIMP3 in non-small cell lung cancer cells.
KDM2B in papillomavirus-related cancer.
KDM2B overexpression correlates with poor prognosis and regulates glioma cell growth.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4 inhibition targets breast cancer stem-like cells.
KDM4/JMJD2 Histone Demethylase Inhibitors Block Prostate Tumor Growth by Suppressing the Expression of AR and BMYB-Regulated Genes.
KDM4/JMJD2 histone demethylases: epigenetic regulators in cancer cells.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4A lysine demethylase induces site-specific copy gain and rereplication of regions amplified in tumors.
KDM4A regulates HIF-1 levels through H3K9me3.
KDM4A, KDM4B and KDM4C in non-small cell lung cancer.
KDM4B plays an important role in mitochondrial apoptosis by upregulating HAX1 expression in colorectal cancer.
KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
KDM4B/JMJD2B is a p53 target gene that modulates the amplitude of p53 response after DNA damage.
KDM4B: A Nail for Every Hammer?
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
KDM4C and ATF4 Cooperate in Transcriptional Control of Amino Acid Metabolism.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
KDM4D Predicts Recurrence in Exocrine Pancreatic Cells of Resection Margins from Patients with Pancreatic Adenocarcinoma.
KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
KDM8, a H3K36me2 histone demethylase that acts in the cyclin A1 coding region to regulate cancer cell proliferation.
Kinetic analysis of iron-dependent histone demethylases: ?-ketoglutarate substrate inhibition and potential relevance to the regulation of histone demethylation in cancer cells.
Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
Long non-coding RNA IRAIN suppresses apoptosis and promotes proliferation by binding to LSD1 and EZH2 in pancreatic cancer.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
Lysine demethylase 2A promotes stemness and angiogenesis of breast cancer by upregulating Jagged1.
Lysine demethylase KDM2A inhibits TET2 to promote DNA methylation and silencing of tumor suppressor genes in breast cancer.
MicroRNAs regulate KDM5 histone demethylases in breast cancer cells.
MINA controls proliferation and tumorigenesis of glioblastoma by epigenetically regulating cyclins and CDKs via H3K9me3 demethylation.
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
miR-491-5p functions as a tumor suppressor by targeting JMJD2B in ER?-positive breast cancer.
MiR137 is an androgen regulated repressor of an extended network of transcriptional coregulators.
Molecular characterization of the porcine JHDM1A gene associated with average daily gain: evaluation its role in skeletal muscle development and growth.
Natural variation in the histone demethylase, KDM4C, influences expression levels of specific genes including those that affect cell growth.
Next-generation sequencing of urine specimens: A novel platform for genomic analysis in patients with non-muscle-invasive urothelial carcinoma treated with bacille Calmette-Guérin.
Novel inhibitors of lysine (K)-specific Demethylase 4A with anticancer activity.
Over-expression of lysine-specific demethylase 1 predicts tumor progression and poor prognosis in human esophageal cancer.
Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer.
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
PARP1-dependent recruitment of KDM4D histone demethylase to DNA damage sites promotes double-strand break repair.
Pathophysiological Response to Hypoxia - From the Molecular Mechanisms of Malady to Drug Discovery:Epigenetic Regulation of the Hypoxic Response via Hypoxia-Inducible Factor and Histone Modifying Enzymes.
PHF2 histone demethylase acts as a tumor suppressor in association with p53 in cancer.
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Pro-growth role of the JMJD2C histone demethylase in HCT-116 colon cancer cells and identification of curcuminoids as JMJD2 inhibitors.
Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
Recognition of trimethylated histone H3 lysine 4 facilitates the recruitment of transcription postinitiation factors and pre-mRNA splicing.
Regional tumour glutamine supply affects chromatin and cell identity.
Regulation of the Histone Demethylase JMJD1A by HIF-1{alpha} Enhances Hypoxic Gene Expression and Tumor Growth.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Role of JMJD2B in colon cancer cell survival under glucose-deprived conditions and the underlying mechanisms.
Screen-identified selective inhibitor of lysine demethylase 5A blocks cancer cell growth and drug resistance.
Silencing the epigenetic silencer KDM4A for TRAIL and DR5 simultaneous induction and antitumor therapy.
Similarity in gene-regulatory networks suggests that cancer cells share characteristics of embryonic neural cells.
SIRT2 suppresses non-small cell lung cancer growth by targeting JMJD2A.
Soybean (Glycine max) prevents the progression of breast cancer cells by downregulating the level of histone demethylase JMJD5.
Stable H3 peptide was delivered by gold nanorods to inhibit LSD1 activation and induce human mesenchymal stem cells differentiation.
Stimulation of ?-catenin and colon cancer cell growth by the KDM4B histone demethylase.
Strong KDM4B and KDM4D Expression Associates with Radioresistance and Aggressive Phenotype in Classical Hodgkin Lymphoma.
Structure-Based Design of a New Scaffold for Cell-Penetrating Peptidic Inhibitors of the Histone Demethylase PHF8.
Structure-Based Discovery of a Selective KDM5A Inhibitor that Exhibits Anti-Cancer Activity via Inducing Cell Cycle Arrest and Senescence in Breast Cancer Cell Lines.
SUMO modification of a heterochromatin histone demethylase JMJD2A enables viral gene transactivation and viral replication.
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
TET2 binds the androgen receptor and loss is associated with prostate cancer.
Tetrazolylhydrazides as Selective Fragment-Like Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A.
The critical role of histone lysine demethylase KDM2B in cancer.
The demethylase JMJD2C localizes to H3K4me3-positive transcription start sites and is dispensable for embryonic development.
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
The Epigenetic Factor KDM2B Regulates EMT and Small GTPases in Colon Tumor Cells.
The histone demethylase Jarid1b is required for hematopoietic stem cell self-renewal.
The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability.
The histone demethylase JMJD2B is regulated by estrogen receptor alpha and hypoxia, and is a key mediator of estrogen induced growth.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
The histone demethylase Kdm3a is required for normal epithelial proliferation, ductal elongation and tumor growth in the mouse mammary gland.
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF.
The histone H3 Lys 27 demethylase KDM6B promotes migration and invasion of glioma cells partly by regulating the expression of SNAI1.
The histone LSD1 demethylase in stemness and cancer transcription programs.
The interplay between the lysine demethylase KDM1A and DNA methyltransferases in cancer cells is cell cycle dependent.
The JmjC domain-containing histone demethylase KDM3A is a positive regulator of the G(1) /S transition in cancer cells via transcriptional regulation of the HOXA1 gene.
The JMJD2A demethylase regulates apoptosis and proliferation in colon cancer cells.
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
The KDM5 family of histone demethylases as targets in oncology drug discovery.
The Lysine Demethylase dKDM2 Is Non-essential for Viability, but Regulates Circadian Rhythms in Drosophila.
The lysine demethylase, KDM4B, is a key molecule in androgen receptor signalling and turnover.
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
The pseudogene derived from long non-coding RNA DUXAP10 promotes colorectal cancer cell growth through epigenetically silencing of p21 and PTEN.
The pseudogene DUXAP10 promotes an aggressive phenotype through binding with LSD1 and repressing LATS2 and RRAD in non small cell lung cancer.
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
The role of the histone demethylase KDM4A in cancer.
The Roles of Histone Demethylase UTX and JMJD3 (KDM6B) In Cancers: Current Progress and Future Perspectives.
The tumor suppressor Rb and its related Rbl2 genes are regulated by Utx histone demethylase.
The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.
Tumor suppression by the histone demethylase UTX.
Tying up tranylcypromine: Novel selective histone lysine specific demethylase 1 (LSD1) inhibitors.
Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
UTX - moonlighting in the cytoplasm?
Utx loss causes myeloid transformation.
Neuralgia
The histone demethylase JMJD2A regulates the expression of BDNF and mediates neuropathic pain in mice.
Neuroblastoma
Histone demethylase KDM6B has an anti-tumorigenic function in neuroblastoma by promoting differentiation.
KDM2B regulates choline kinase expression and neuronal differentiation of neuroblastoma cells.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A.
Targeted inhibition of histone H3K27 demethylation is effective in high-risk neuroblastoma.
The role of histone demethylase KDM4B in Myc signaling in neuroblastoma.
Neurodegenerative Diseases
Epigenomic networking in drug development: from pathogenic mechanisms to pharmacogenomics.
Targeting Histone Demethylase LSD1/KDM1a in Neurodegenerative Diseases.
Neurofibrosarcoma
Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Non-alcoholic Fatty Liver Disease
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Obesity
Commentary: The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Correction for Cheng et al., KDM4B protects against obesity and metabolic dysfunction.
Fasting-induced JMJD3 histone demethylase epigenetically activates mitochondrial fatty acid ?-oxidation.
Histone Demethylase JHDM2A Is Involved in Male Infertility and Obesity.
Histone demethylase KDM3a, a novel regulator of vascular smooth muscle cells, controls vascular neointimal hyperplasia in diabetic rats.
Interplay among H3K9-editing enzymes SUV39H1, JMJD2C and SRC-1 drives p66Shc transcription and vascular oxidative stress in obesity.
JMJD2B/KDM4B inactivation in adipose tissues accelerates obesity and systemic metabolic abnormalities.
KDM4B protects against obesity and metabolic dysfunction.
Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice.
Regulation of adipogenesis by nuclear receptor PPAR? is modulated by the histone demethylase JMJD2C.
The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity.
Osteoporosis
Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs.
Osteosarcoma
Histone Demethylase JARID1B is Overexpressed in Osteosarcoma and Upregulates Cyclin D1 Expression Via Demethylation of H3K27me3.
Histone demethylase JMJD2B and JMJD2C induce fibroblast growth factor 2: mediated tumorigenesis of osteosarcoma.
Histone demethylase JMJD2C: epigenetic regulators in tumors.
Regulation of tumor suppressor p53 and HCT116 cell physiology by histone demethylase JMJD2D/KDM4D.
Ovarian Neoplasms
Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer.
Crystal structures of PRK1 in complex with the clinical compounds lestaurtinib and tofacitinib reveal ligand induced conformational changes.
Histone demethylase KDM2B upregulates histone methyltransferase EZH2 expression and contributes to the progression of ovarian cancer in vitro and in vivo.
Lysine demethylase 2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelial?mesenchymal transition.
Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.
The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.
Pancreatic Neoplasms
circZMYM2 Competed Endogenously with miR-335-5p to Regulate JMJD2C in Pancreatic Cancer.
KDM2B promotes pancreatic cancer via Polycomb-dependent and -independent transcriptional programs.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
Loss of histone demethylase KDM6B enhances aggressiveness of pancreatic cancer through downregulation of C/EBP?
Polycythemia Vera
Polycythemia vera transforming to acute myeloid leukemia and complex abnormalities including 9p homogeneously staining region with amplification of MLLT3, JMJD2C, JAK2, and SMARCA2.
Pre-Eclampsia
Compromised JMJD6 histone demethylase activity impacts on VHL gene repression in preeclampsia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
The histone demethylase PHF8 promotes adult acute lymphoblastic leukemia through interaction with the MEK/ERK signaling pathway.
Transcriptional Regulation of JARID1B/KDM5B Histone Demethylase by Ikaros, Histone Deacetylase 1 (HDAC1), and Casein Kinase 2 (CK2) in B-cell Acute Lymphoblastic Leukemia.
Prostatic Intraepithelial Neoplasia
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Prostatic Neoplasms
A three-gene signature and clinical outcome in esophageal squamous cell carcinoma.
Activation of androgen receptor by histone demethylases JMJD2A and JMJD2D.
ATR inhibition controls aggressive prostate tumors deficient in Y-linked histone demethylase KDM5D.
c-MYC drives histone demethylase PHF8 during neuroendocrine differentiation and in castration-resistant prostate cancer.
Chem-seq permits identification of genomic targets of drugs against androgen receptor regulation selected by functional phenotypic screens.
Cooperation between ETS variant 2 and Jumonji domain?containing 2 histone demethylases.
Epigenetic therapy in urologic cancers: an update on clinical trials.
ETS transcription factor ERG cooperates with histone demethylase KDM4A.
EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.
Genetic alterations and changes in expression of histone demethylases in prostate cancer.
Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells.
Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1.
Histone demethylase KDM7A controls androgen receptor activity and tumor growth in prostate cancer.
KDM3A is not associated with metastasis and prognosis of breast cancer.
KDM4A Coactivates E2F1 to Regulate the PDK-Dependent Metabolic Switch between Mitochondrial Oxidation and Glycolysis.
KDM4B as a target for prostate cancer: structural analysis and selective inhibition by a novel inhibitor.
Lgr4 promotes prostate tumorigenesis through the Jmjd2a/AR signaling pathway.
LSD1 inhibition attenuates androgen receptor V7 splice variant activation in castration resistant prostate cancer models.
MiR-10a functions as a tumor suppressor in prostate cancer via targeting KDM4A.
Overexpression of lysine-specific demethylase 1 promotes androgen-independent transition of human prostate cancer LNCaP cells through activation of the AR signaling pathway and suppression of the p53 signaling pathway.
Regulation of c-Myc expression by the histone demethylase JMJD1A is essential for prostate cancer cell growth and survival.
Systematic knockdown of epigenetic enzymes identifies a novel histone demethylase PHF8 overexpressed in prostate cancer with an impact on cell proliferation, migration and invasion.
The epigenetic factor KDM2B regulates cell adhesion, small rho GTPases, actin cytoskeleton and migration in prostate cancer cells.
The histone demethylase KDM3A regulates the transcriptional program of the androgen receptor in prostate cancer cells.
The histone demethylase PHF8 promotes prostate cancer cell growth by activating the oncomiR miR-125b.
The JMJD3 Histone Demethylase and the EZH2 Histone Methyltransferase in Prostate Cancer.
The lysine specific demethylase-1 (LSD1/KDM1A) regulates VEGF-A expression in prostate cancer.
Upregulation of PSMD10 caused by the JMJD2A histone demethylase.
Whole transcriptome sequencing reveals extensive unspliced mRNA in metastatic castration-resistant prostate cancer.
Respiratory Insufficiency
The histone demethylase Jarid1b ensures faithful mouse development by protecting developmental genes from aberrant H3K4me3.
Retinoblastoma
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase retinoblastoma binding protein 2 is overexpressed in hepatocellular carcinoma and negatively regulated by hsa-miR-212.
Histone demethylase retinoblastoma binding protein 2 regulates the expression of ?-smooth muscle actin and vimentin in cirrhotic livers.
Inhibition of osteogenic differentiation of human adipose-derived stromal cells by retinoblastoma binding protein 2 repression of RUNX2-activated transcription.
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
miR-137 Modulates a Tumor Suppressor Network-Inducing Senescence in Pancreatic Cancer Cells.
RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2.
The retinoblastoma binding protein RBP2 is an H3K4 demethylase.
Sarcoma, Ewing
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
KDM3A is not associated with metastasis and prognosis of breast cancer.
The histone demethylase KDM3A is a microRNA-22-regulated tumor promoter in Ewing Sarcoma.
The histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.
The Jumonji-domain histone demethylase inhibitor JIB-04 deregulates oncogenic programs and increases DNA damage in Ewing Sarcoma, resulting in impaired cell proliferation and survival, and reduced tumor growth.
Sarcoma, Synovial
The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Scleroderma, Systemic
The histone demethylase Jumonji domain-containing protein 3 (JMJD3) regulates fibroblast activation in systemic sclerosis.
Shock, Septic
Endogenous hydrogen sulfide regulates histone demethylase JMJD3-mediated inflammatory response in LPS-stimulated macrophages and in a mouse model of LPS-induced septic shock.
Histone demethylase LSD1 regulates hematopoietic stem cells homeostasis and protects from death by endotoxic shock.
Skin Neoplasms
The oncogenic role of GASC1 in chemically induced mouse skin cancer.
Spondylitis, Ankylosing
The histone demethylase JARID1A is associated with susceptibility to ankylosing spondylitis.
Squamous Cell Carcinoma of Head and Neck
[Sonic hedgehog signaling enhanced the expression of histone demethylase, lysine-specific demethylase 8 in the head and neck squamous cell carcinoma cell line SCC-6].
Starvation
A CxxC Domain That Binds to Unmethylated CpG Is Required for KDM2A to Control rDNA Transcription.
CxxC-ZF Domain Is Needed for KDM2A to Demethylate Histone in rDNA Promoter in Response to Starvation.
Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis.
Inhibition of histone demethylase JMJD1A improves anti-angiogenic therapy and reduces tumor associated macrophages.
Stomach Neoplasms
Comparative integromics on JMJD1C gene encoding histone demethylase: conserved POU5F1 binding site elucidating mechanism of JMJD1C expression in undifferentiated ES cells and diffuse-type gastric cancer.
Critical role of histone demethylase RBP2 in human gastric cancer angiogenesis.
Histone demethylase JMJD2B is required for tumor cell proliferation and survival and is overexpressed in gastric cancer.
Histone demethylase JMJD2B-mediated cell proliferation regulated by hypoxia and radiation in gastric cancer cell.
Histone demethylase KDM2A promotes tumor cell growth and migration in gastric cancer.
Histone demethylase PHF8 promotes progression and metastasis of gastric cancer.
Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis.
Histone demethylase RBP2 promotes malignant progression of gastric cancer through TGF-?1-(p-Smad3)-RBP2-E-cadherin-Smad3 feedback circuit.
Inhibition of cell proliferation and induction of autophagy by KDM2B/FBXL10 knockdown in gastric cancer cells.
JMJD2A predicts prognosis and regulates cell growth in human gastric cancer.
JMJD2B is required for Helicobacter pylori-induced gastric carcinogenesis via regulating COX-2 expression.
JMJD2B promotes epithelial-mesenchymal transition by cooperating with ?-catenin and enhances gastric cancer metastasis.
KDM4B is a coactivator of c-Jun and involved in gastric carcinogenesis.
KDM4B promotes epithelial-mesenchymal transition through up-regulation of ZEB1 in pancreatic cancer.
KDM4B promotes gastric cancer metastasis by regulating miR-125b-mediated activation of Wnt signaling.
MicroRNA-212 inhibits proliferation of gastric cancer by directly repressing retinoblastoma binding protein 2.
MiR-448 promotes glycolytic metabolism of gastric cancer by downregulating KDM2B.
MiRNA-491-5p inhibits cell proliferation, invasion and migration via targeting JMJD2B and serves as a potential biomarker in gastric cancer.
The histone demethylase lysine-specific demethylase-1-mediated epigenetic silence of KLF2 contributes to gastric cancer cell proliferation, migration, and invasion.
The histone demethylase RBP2 is over-expressed in gastric cancer and its inhibition triggers senescence of cancer cells.
Systemic Vasculitis
Correction: Cross-phenotype analysis of Immunochip data identifies KDM4C as a relevant locus for the development of systemic vasculitis.
Teratocarcinoma
LSD1 demethylase and the methyl-binding protein PHF20L1 prevent SET7 methyltransferase-dependent proteolysis of the stem-cell protein SOX2.
Testicular Neoplasms
PLU-1/JARID1B overexpression predicts proliferation properties in head and neck squamous cell carcinoma.
Tics
Activation of PKA leads to mesenchymal-to-epithelial transition and loss of tumor-initiating ability.
Triple Negative Breast Neoplasms
Histone demethylase KDM2B promotes triple negative breast cancer proliferation by suppressing p15INK4B, p16INK4A, and p57KIP2 transcription.
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancer.
KDM4C Activity Modulates Cell Proliferation and Chromosome Segregation in Triple-Negative Breast Cancer.
Kdm4c is Recruited to Mitotic Chromosomes and Is Relevant for Chromosomal Stability, Cell Migration and Invasion of Triple Negative Breast Cancer Cells.
Overexpression of histone demethylase JMJD5 promotes metastasis and indicates a poor prognosis in breast cancer.
Urinary Bladder Neoplasms
Analyses of publicly available genomics resources define FGF-2-expressing bladder carcinomas as EMT-prone, proliferative tumors with low mutation rates and high expression of CTLA-4, PD-1 and PD-L1.
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
Deregulation of the histone demethylase JMJD2A is involved in human carcinogenesis through regulation of the G(1)/S transition.
Histone demethylase JMJD1A promotes urinary bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1?.
Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer.
Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer.
The histone demethylase JMJD2B plays an essential role in human carcinogenesis through positive regulation of cyclin-dependent kinase 6.
Uterine Cervical Neoplasms
HPV16 E6 and E7 upregulate the histone lysine demethylase KDM2B through the c-MYC/miR-146a-5p axys.
JMJD2A facilitates growth and inhibits apoptosis of cervical cancer cells by downregulating tumor suppressor miR?491?5p.
KDM3A is associated with tumor metastasis and modulates colorectal cancer cell migration and invasion.
Uterine Neoplasms
JMJD2B as a potential diagnostic immunohistochemical marker for hepatocellular carcinoma: a tissue microarray-based study.
Vascular System Injuries
Critical role of histone demethylase JMJD3 in the regulation of neointima formation following vascular injury.
Virus Diseases
Histone demethylase LSD1 regulates hematopoietic stem cells homeostasis and protects from death by endotoxic shock.
Inhibition of LSD1 reduces herpesvirus infection, shedding, and recurrence by promoting epigenetic suppression of viral genomes.
Synthesis, biological activity and mechanistic insights of 1-substituted cyclopropylamine derivatives: a novel class of irreversible inhibitors of histone demethylase KDM1A.
T Follicular Helper Cell-Dependent Clearance of a Persistent Virus Infection Requires T Cell Expression of the Histone Demethylase UTX.
[histone-h3]-lysine-36 demethylase deficiency
Phf8 histone demethylase deficiency causes cognitive impairments through the mTOR pathway.